mk 3475 - Robuta Search

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT04003636&r=1 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for... Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract... mk 3475 pembrolizumab plus gemcitabine cisplatin https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02054806 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors... Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) mk 3475 study pembrolizumab https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02358031&r=1 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous... A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02362594&r=1 Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III... Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) https://www.mayo.edu/research/clinical-trials/cls-20145329?&p=1 Study Of Pembrolizumab (MK-3475) Compared To Platinum-Based Chemotherapies In Participants With... https://stanfordhealthcare.org/trials/p/NCT02506153.html Phase III High Dose Interferon or Ipilimumab vs MK-3475(Pembrolizumab) in HighRisk Resected Melanoma Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02853331&r=1 Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib... Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02358031 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous... A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)